AUA 2024: Dr. Weiner previews key prostate cancer research

In this video, Adam B. Weiner, MD, highlights 5 studies in prostate cancer that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Weiner is a current urologic oncology fellow at the University of California, Los Angeles.

During the discussion, Weiner highlights the following presentations:

• P2s: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
• P2s: Apalutamide and androgen deprivation therapy for the treatment of high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm ph
• PD01-03: Third interim analysis (IA3) of the DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
• PD01-06: Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis
• PD39-06: A randomized clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. Intention to treat analysis at two-year follow-up